In a phase 2 basket RCT of oligometastatic disease (1-5 metastases; 334 analysed per protocol), adding metastasis-directed therapy (98% radiotherapy) to standard care improved PFS (HR 0.54; median follow-up 53 months). Breast and kidney baskets were inconclusive.
RCTn = 350
Sherry et al. Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial